Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385804 | 0.93 | CYP2C8 (0.47) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19385795 | 0.93 | CYP2C8 (0.51) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19385788 | 0.93 | CYP2C8 (0.51) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19401335 | 0.92 | CYP2C8 (0.49) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19385812 | 0.91 | CYP2C8 (0.49) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19385859 | 0.91 | CYP2C8 (0.50) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19401323 | 0.91 | CYP2C8 (0.48) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19385900 | 0.90 | CYP2C8 (0.48) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19401372 | 0.90 | CYP2C8 (0.38) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL19385706 | 0.89 | CYP2C8 (0.56) | CYP2C8CYP3A4KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017165233-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | CYP2C8 57/4885CYP3A4 94/4885KCNH2 3469/4885 |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | HAVCR2, UGT2B7, GOT1 | CYP2C8 57/4885CYP3A4 94/4885KCNH2 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.